Fiduciary Group LLC lowered its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,562 shares of the biopharmaceutical company’s stock after selling 367 shares during the quarter. Fiduciary Group LLC’s holdings in Bristol-Myers Squibb were worth $1,341,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Lodestar Investment Counsel LLC IL increased its position in shares of Bristol-Myers Squibb by 5.2% during the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after purchasing an additional 5,579 shares during the last quarter. Perella Weinberg Partners Capital Management LP increased its holdings in Bristol-Myers Squibb by 10.9% in the 1st quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 1,905 shares in the last quarter. Stephens Inc. AR increased its holdings in Bristol-Myers Squibb by 30.7% in the 1st quarter. Stephens Inc. AR now owns 216,532 shares of the biopharmaceutical company’s stock worth $10,331,000 after acquiring an additional 50,798 shares in the last quarter. Nachman Norwood & Parrott Inc increased its holdings in Bristol-Myers Squibb by 3.5% in the 2nd quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock worth $2,285,000 after acquiring an additional 1,687 shares in the last quarter. Finally, Edge Wealth Management LLC increased its holdings in Bristol-Myers Squibb by 217.7% in the 2nd quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock worth $452,000 after acquiring an additional 6,857 shares in the last quarter. 80.11% of the stock is owned by hedge funds and other institutional investors.
BMY traded up $0.57 during trading on Monday, reaching $47.55. 177,241 shares of the company traded hands, compared to its average volume of 14,942,915. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $63.69. The firm has a fifty day simple moving average of $45.33 and a 200 day simple moving average of $47.45. The company has a market cap of $74.84 billion, a P/E ratio of 11.91, a PEG ratio of 2.26 and a beta of 0.73.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same period last year, the firm posted $1.01 EPS. The company’s revenue was up 10.0% on a year-over-year basis. As a group, sell-side analysts expect that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.
In related news, Director Robert J. Bertolini acquired 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average cost of $44.72 per share, with a total value of $491,920.00. Following the acquisition, the director now directly owns 11,397 shares in the company, valued at approximately $509,673.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.
Several research firms recently issued reports on BMY. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a report on Wednesday, August 14th. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price for the company. in a report on Monday, May 20th. JPMorgan Chase & Co. began coverage on shares of Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price for the company. Barclays raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $55.88.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.